The Cooper Companies, Inc. is a global medical device company operating through two main business segments: CooperVision and CooperSurgical. CooperVision focuses on the vision correction market, developing, manufacturing, and marketing a wide range of soft contact lenses, including products like the MiSight 1 day lens, which is FDA-approved for slowing myopia progression in children . CooperSurgical specializes in fertility and women's health, offering products and services such as medical devices, fertility products, cryostorage services, and contraception solutions like the PARAGARD IUD . The company continues to expand its market presence through strategic acquisitions and product innovations in both segments .
- CooperVision - Develops, manufactures, and markets a wide range of soft contact lenses, including spherical, toric, multifocal, and myopia management lenses.
- MiSight 1 day lens - FDA-approved lens designed to slow myopia progression in children.
- MyDay - A product line contributing significantly to the company's revenue.
- Biofinity - Another key product line in the vision correction market.
- CooperSurgical - Focuses on fertility and women's health, offering a diverse portfolio of products and services.
- Fertility Products - Includes medical devices and cryostorage services.
- Contraception Solutions - Features products like the PARAGARD IUD.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Albert G. White III ExecutiveBoard | President & CEO | Board Member at Evolus Inc. | Joined COO in 2006; became CEO in May 2018. Previously held roles such as CFO and Chief Strategy Officer. Holds a B.S. in Finance and MBA from Virginia Tech. | View Report → |
Brian G. Andrews Executive | EVP, CFO & Treasurer | None | Joined COO in 2006; became CFO in December 2020. Previously held roles such as Assistant Treasurer and VP, Global Logistics. | |
Daniel G. McBride Executive | EVP & Chief Operating Officer (COO) | Board Member at Optometry Giving Sight | Joined COO in 2005; became COO in November 2013. Previously served as President of CooperVision and General Counsel. | |
Holly R. Sheffield Executive | President, CooperSurgical | Board Member at Imperative Care, Inc. and AdvaMed | Joined COO in 2018; became President of CooperSurgical in July 2020. Previously EVP & Chief Strategy Officer. Holds a B.S. from Cornell and MBA from Columbia. | |
Colleen E. Jay Board | Independent Director | Board Member at Treasury Wine Estates and Beyond Meat, Inc. | Joined COO's board in April 2016. Former Global Division President at Procter & Gamble. Brings expertise in consumer goods and international business. | |
Cynthia L. Lucchese Board | Independent Director | Board Member at Inari Medical, Relievant Medsystems, and Beaver-Visitec | Joined COO's board in October 2022. Former CFO at Hillenbrand and Thoratec. Brings financial and governance expertise. | |
Lawrence E. Kurzius Board | Independent Director | Executive Chairman at McCormick & Co.; Board Member at Elanco Animal Health | Joined COO's board in December 2023. Former CEO of McCormick & Co. Brings expertise in global business strategy and operations. | |
Maria Rivas, M.D. Board | Independent Director | Global Chief Medical Affairs Officer at Pfizer (retiring March 2025) | Joined COO's board in 2021. Brings expertise in women’s healthcare and medical affairs. Former director at Medidata. | |
Teresa S. Madden Board | Independent Director | Board Member at Enbridge, Inc. | Joined COO's board in December 2020. Former CFO of Xcel Energy. Chairs the Audit Committee. | |
William A. Kozy Board | Vice Chairman & Lead Director | Chairman of LivaNova PLC; Senior Advisor to McKinsey & Company | Joined COO's board in 2016. Former COO of Becton Dickinson. Announced retirement effective April 2025. |
-
Given the unexpected revenue softness at the end of Q4 and the potential impact of recent price increases, can you provide more detail on how your pricing strategy is affecting consumer buying behavior and what measures you're taking to mitigate any potential negative effects on revenues?
-
With competitors accelerating their product launches and expanding their portfolios, how confident are you in your current pipeline and global launch strategy to maintain and grow your market share, and can you elaborate on specific new products or innovations that will differentiate you in fiscal 2025?
-
You mentioned that CooperSurgical faced challenges with the Q2 IT system upgrade that impacted operations; can you discuss how these issues affected your financial performance and operational efficiency, and what steps have been implemented to prevent similar disruptions in the future?
-
Considering that the recent acquisitions contributing approximately $25 million in annualized revenue are now part of the organic base and the M&A environment is currently quiet, how do you plan to drive growth organically in fiscal 2025, and what strategies are in place to compensate for the reduced contribution from acquisitions?
-
While you've indicated minimal exposure to tariffs from manufacturing in China, Mexico, or Canada, how are you assessing and mitigating potential supply chain and geopolitical risks in other regions where you have manufacturing facilities to ensure uninterrupted operations and protect your margins?
Research analysts who have asked questions during COOPER COMPANIES earnings calls.
Brett Fishbin
KeyBanc Capital Markets
5 questions for COO
Jason Bednar
Piper Sandler Companies
5 questions for COO
Jeffrey Johnson
Robert W. Baird & Co. Inc.
5 questions for COO
Jonathan Block
Stifel Financial Corp.
5 questions for COO
Craig Bijou
Bank of America Securities
4 questions for COO
David Saxon
Needham & Company
4 questions for COO
Issie Kirby
Redburn Atlantic
4 questions for COO
Joanne Wuensch
Citigroup Inc.
4 questions for COO
Larry Biegelsen
Wells Fargo & Company
4 questions for COO
Navann Ty
BNP Paribas S.A.
4 questions for COO
Robert Marcus
JPMorgan Chase & Co.
4 questions for COO
Steven Lichtman
Oppenheimer & Co. Inc.
4 questions for COO
Anthony Petrone
Mizuho Group
3 questions for COO
Christopher Pasquale
Nephron Research
3 questions for COO
Patrick Wood
Morgan Stanley
3 questions for COO
Young Li
Jefferies
3 questions for COO
Chris Pasquale
Nephron Research LLC
2 questions for COO
Bradley Bowers
Mizuho Securities USA LLC
1 question for COO
Lawrence Biegelsen
Wells Fargo
1 question for COO
Navann Ty Dietschi
BNP Paribas
1 question for COO
Robbie Marcus
JPMorgan Chase & Co.
1 question for COO
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Johnson & Johnson Vision Care, Inc. | The company is one of the largest competitors in the worldwide market and a primary competitor in the spherical, toric, and multifocal lens categories. It may have substantially greater financial resources, larger research and development budgets, larger sales forces, greater market penetration, and/or larger manufacturing volumes than CooperVision. They offer competitive products and differentiated materials, plus a variety of other eye care products including lens care products and ophthalmic pharmaceuticals, which may give them a competitive advantage in marketing their lenses. |
The company is one of the largest competitors in the worldwide market and a primary competitor in the spherical, toric, and multifocal lens categories. It may have substantially greater financial resources, larger research and development budgets, larger sales forces, greater market penetration, and/or larger manufacturing volumes than CooperVision. | |
The company is one of the largest competitors in the worldwide market and a primary competitor in the spherical, toric, and multifocal lens categories. It may have substantially greater financial resources, larger research and development budgets, larger sales forces, greater market penetration, and/or larger manufacturing volumes than CooperVision. | |
Vitrolife Group | The company competes with CooperSurgical in the fertility market. |
FujiFilm-Irvine Scientific | The company competes with CooperSurgical in the fertility market. |
Hamilton Thorne | The company competes with CooperSurgical in the fertility market. |
Fairfax Cryobank and Fairfax EggBank | The company competes with CooperSurgical in the fertility market. |
ViaCord | A division of Revvity, the company competes primarily with CooperSurgical in the stem cell storage field in the United States. |
Bayer | The company competes with CooperSurgical's Paragard with its hormonal IUDs. |
The company competes with CooperSurgical's Paragard with its hormonal IUDs. | |
The company competes with CooperSurgical's Paragard with its Long Acting Reversible Contraceptives. | |
The company has offerings that compete with CooperSurgical's medical device products. | |
The company has offerings that compete with CooperSurgical's medical device products. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
obp Surgical | 2024 | CooperSurgical acquired obp Surgical for approximately $100.0 million, including developed technology, customer relationships, inventory, and significant goodwill aimed at expanding its portfolio in women’s health surgical solutions. |
ZyMot Fertility | 2024 | The acquisition of ZyMot Fertility for about $33.5 million provided CooperSurgical with specialized sperm separation technologies and intangible assets (valued at $39.6 million) that are expected to drive revenue growth post-acquisition. |
Private Denmark-based Contact Lens Distributor | 2022 | Completed in fiscal 2022, this acquisition by CooperVision targeted a distributor specializing in orthokeratology and scleral contact lenses to enhance its specialty eye care portfolio in the Nordic market. |
Private Cryopreservation Services Company | 2022 | Completed on April 6, 2022, this acquisition aligns with CooperSurgical’s strategy by adding cryogenic services to its portfolio, with preliminary purchase price allocations for intangible assets, PPE, and associated goodwill. |
Cook Medical's Reproductive Health Business | 2022 | Acquired in 2022 for a total consideration of $875 million (structured with an upfront cash payment and deferred installments), this deal bolsters CooperSurgical’s international fertility presence and labor/delivery portfolio while expecting earnings accretion. |
Generate Life Sciences | 2022 | Acquired on December 17, 2021 (reported in the 2022 timeline) for approximately $1.663 billion, this transaction—funded by a senior unsecured term loan and cash—expanded CooperSurgical’s offerings in donor gametes, fertility cryopreservation, and newborn stem cell storage, and introduced substantial goodwill and long-term customer relationships. |
Recent press releases and 8-K filings for COO.
- Q3 CooperVision organic growth was 2% vs. ~5% expected, driven by accelerated private-label Clarity drawdown in Asia Pac and normalization of six-month to two-month e-commerce channel inventory in China; Q4 guidance is conservatively built to offset these factors.
- MyDay supply constraints have been fully resolved as of May, enabling double-digit MyDay growth and supporting ~25% global market share in daily silicone hydrogel lenses.
- Management expects the global contact lens market to grow 4–6% in FY26, CooperVision core in line with market plus 100 bps from MiSight, with daily wear penetration at ~40% globally and runway to 50%+.
- Targeting $2 billion of free cash flow over three years, with declining CapEx; primary uses include debt paydown and increased share repurchases, supported by a CooperSurgical reorganization to improve margins and offset ~$24 million in tariffs.
- Global Focus: Cooper Companies Inc, a global medical device firm, highlighted its dual focus on vision (contact lenses including a broad range of toric and multifocal lenses) and women's health (fertility and OB/GYN surgical products).
- Guidance & Market Dynamics: The company updated its guidance due to evolving market conditions and inventory dynamics, with expectations for lower contact lens market growth compared to past projections.
- Product & Investment Initiatives: Emphasis was placed on new product initiatives, such as the launch of the Energous offering and aggressive strategies around MiSight for myopia control, alongside significant capacity investments for manufacturing and distribution.
- The OECD cut global GDP growth forecasts to 2.9% for both 2025 and 2026, down from previous projections above 3%.
- The US economy is projected to slow to 1.6% in 2025 and 1.5% in 2026 as higher tariffs dampen investment, consumer spending, and job growth.
- The US effective tariff rate on imports has jumped to 15.4%, its highest level since 1938, which is expected to weigh on consumption and business investment.
- The OECD warned that rising trade barriers and policy uncertainty have undermined confidence, urging constructive negotiations to stabilize global markets.
- Iran’s 60% enriched uranium stockpile rose by about 50%, from 274.8 kg to 408.6 kg, enough for roughly 10 nuclear weapons.
- The US proposed a new nuclear deal via Omani mediation, demanding an end to Iran’s enrichment in exchange for phased sanctions relief; Iran rejected halting enrichment as one-sided.
- The US has paused new sanctions pending Iran’s response, though President Trump warned of military action if talks fail and urged Israel not to strike Iranian sites.
- Regional tensions persist, with reports that Israel may consider unilateral action against Iran’s nuclear facilities.
- Revised fiscal 2025 guidance: Total revenue is expected to be between $4,107 and $4,146 million with organic growth of 5%-6%.
- Segment details: CooperVision is guided to deliver revenue between $2,759 and $2,786 million with 6%-7% organic growth, while CooperSurgical’s revenue guidance is $1,347 to $1,359 million with 3.5%-4.5% growth; non-GAAP EPS is projected to be between $4.05 and $4.11.